Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per ...

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

SAN DIEGO - Inhibrx Biosciences, Inc. (NASDAQ: INBX), a clinical-stage biopharmaceutical company valued at $195 million, ...

Inhibrx (INBX) announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart in combination with Folfiri for the treatment ...

1Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: John Paul Shen, Department of Colon and Rectal Surgery, The ...

1Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. 2Clinical Research Center for Colorectal Cancer in Heilongjiang, Harbin, China. 3Key ...

#stankostrong…” On April 29, 2024, Jonathan Stanko received a diagnosis of stage four Adenocarcinoma gastric cancer. On May 10, 2024, he shared his journey in a blog post. Jonathan Stanko ...

The drug candidate is being developed based on the ADC conjugation technology. It was under development for the treatment of pancreatic ductal adenocarcinoma, colorectal cancer and bladder cancer.